Funding to Enhance Research and Development of Pipeline, Including Lead Program Targeting Activated KRASG12C. Proceeds to Further Accelerate the Development of Foundational Technologies in Chemoproteomics, Covalent Drug Discovery and Machine Learning. Distinguished Scientific Advisory Board Announced. Expansion of Frontier Operations with Opening of Boston Facility...

George Golumbeski has joined the Droia partnership to reinforce the team with the launch of the new fund. Golumbeski is the former Executive Vice President of Business Development at Celgene, where he was a major architect of Celgene’s successful biotech collaboration and acquisition strategy. Post...

“The support of our new and existing investors reflects the increasing interest around CIN as a core driver in cancer biology,” said Charles Hugh-Jones, M.D., Volastra’s Chief Executive Officer. “This latest financing places us in a position of strength to advance our bold vision to...

“We are intrigued by the potential of RAD-51 inhibition, particularly due to early findings suggesting it could be helpful in treating lymphomas and other hematologic malignancies,” said Derek DiRocco, Ph.D., partner, RA Capital Management. “This promising mechanism, coupled with the demonstrated efficiency and expertise of...